ADXN קפיטליזציה חשבונאית Addex Therapeutics Ltd

The current state of Addex Therapeutics (ADXN) relies on partner payments, which provide temporary support for the company in the absence of its own products. The biotech's strategy focuses on developing precision treatments for dystonia and Parkinson's disease. The price action on GURU.Markets, where the indicator stands at 0.00, depends on the outcomes of tests with Janssen and the prospects of receiving royalties for receptor modulation.

Book value capitalization reflects the actual value of Addex Therapeutics (ADXN) net assets minus all liabilities, allowing investors to filter out market noise and assess the business's intrinsic stability. By analyzing changes in the book value of equity, one can diagnose the effectiveness of investments in green drug synthesis and the implementation of zero-waste laboratory technologies, which minimize chemical disposal costs.